Literature DB >> 29844906

Diagnostic and treatment hurdles in plasma cell myeloma with t(11;14) translocation: A case report.

Shun Yin Kong1, Wing Kit Lam2, Ka Shu Li1, Ka Pik Yeung1, Chung Yin Ha1, Ho Kei Lai1, Hay Nun Chan1, Yiu Ming Yeung1, Sze Fai Yip1,2.   

Abstract

t(11;14) translocation is one of the most common chromosomal abnormalities in plasma cell myeloma. The present case report presented a case of plasma cell myeloma with t(11;14) translocation, in which the plasma cells were small lymphoplasmacytoids in morphology with positive cluster of differentiation-20 and Cyclin D1 expression. These results led to initial diagnostic difficulties. The patient was refractory to bortezomib-based therapy, and responsive to vincristine, doxorubicin and dexamethasone. However, the prognostic value of t(11;14) in plasma cell myeloma remains to be determined. With recent advances in treatment options, physicians should be aware of the clinical and pathological characteristics of this translocation in plasma cell myeloma.

Entities:  

Keywords:  Cyclin D1; cluster of differentiation 20; plasma cell myeloma; t(11;14)

Year:  2018        PMID： 29844906      PMCID： PMC5958828          DOI： 10.3892/mco.2018.1612

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN： 2049-9450


  12 in total

1.  The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.

Authors:  J D Hoyer; C A Hanson; R Fonseca; P R Greipp; G W Dewald; P J Kurtin
Journal:  Am J Clin Pathol       Date:  2000-06       Impact factor: 2.493

2.  CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

Authors:  Nelly Robillard; Herve Avet-Loiseau; Richard Garand; Philippe Moreau; Danielle Pineau; Marie-Josee Rapp; Jean-Luc Harousseau; Regis Bataille
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

3.  Rituximab in CD20 positive multiple myeloma.

Authors:  P Moreau; L Voillat; L Benboukher; C Mathiot; C Dumontet; N Robillard; O Hérault; F Garnache; R Garand; N Varoqueaux; H Avet-Loiseau; J L Harousseau; R Bataille
Journal:  Leukemia       Date:  2007-02-01       Impact factor: 11.528

4.  Rituximab in CD20 positive multiple myeloma.

Authors:  J M Bergua; C Cabrera; E G Arteta; J Prieto
Journal:  Leukemia       Date:  2007-11-01       Impact factor: 11.528

5.  Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.

Authors:  G P Kaufman; M A Gertz; A Dispenzieri; M Q Lacy; F K Buadi; D Dingli; S R Hayman; P Kapoor; J A Lust; S Russell; R S Go; Y L Hwa; R A Kyle; S V Rajkumar; S K Kumar
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

6.  Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

Authors:  Rafael Fonseca; Emily A Blood; Martin M Oken; Robert A Kyle; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; James D Hoyer; David Harrington; Neil E Kay; Brian Van Ness; Philip R Greipp
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

7.  CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.

Authors:  Steven P Treon; Linda M Pilarski; Andrew R Belch; Abigail Kelliher; Frederic I Preffer; Yoshihito Shima; Constantine S Mitsiades; Nicholas S Mitsiades; Agnieszka J Szczepek; Leonard Ellman; David Harmon; Michael L Grossbard; Kenneth C Anderson
Journal:  J Immunother       Date:  2002 Jan-Feb       Impact factor: 4.456

8.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

Authors:  Philippe Moreau; Thierry Facon; Xavier Leleu; Nadine Morineau; Pauline Huyghe; Jean-Luc Harousseau; Régis Bataille; Hervé Avet-Loiseau
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

9.  MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.

Authors:  Fatima Hamadeh; Stephen P MacNamara; Nadine S Aguilera; Steven H Swerdlow; James R Cook
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

10.  Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Authors:  Shaji Kumar; Jonathan L Kaufman; Cristina Gasparetto; Joseph Mikhael; Ravi Vij; Brigitte Pegourie; Lofti Benboubker; Thierry Facon; Martine Amiot; Philippe Moreau; Elizabeth A Punnoose; Stefanie Alzate; Martin Dunbar; Tu Xu; Suresh K Agarwal; Sari Heitner Enschede; Joel D Leverson; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Cyrille Touzeau
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.